摘要
sotorasib是一种针对Kirsten大鼠肉瘤原癌基因(KRAS) G12C突变的抑制剂,于2021年5月28日获美国食品和药物管理局批准上市,用于治疗KRAS G12C突变、既往至少接受过一种全身治疗的局部晚期或转移性非小细胞肺癌(NSCLC)成年患者。最新临床研究表明,接受sotorasib治疗的NSCLC患者中位缓解持续时间为11.1个月,中位无进展生存期为12.5个月,客观缓解率为37.1%(46/124),疾病控制率为80.6%(100/124)。其主要不良事件包括腹泻、肌肉骨骼疼痛、恶心、疲劳、肝毒性和咳嗽等。
Sotorasib is an inhibitor for KRAS G12C mutation.It was approved by the U.S.Food and Drug Adminstration for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer(NSCLC)with KRAS G12C mutation who have received at least one systemic treatment on May 28,2021.The latest clinical studies have shown that the median remission duration of NSCLC patients treated with sotorasib was 11.1 months,the median progression free survival was 12.5 months,the objective remission rate was 37.1%(46/124),and the disease control rate was 80.6%(100/124).The main adverse events of sotorasib include diarrhea,musculoskeletal pain,nausea,fatigue,hepatotoxicity,cough,and so on.
作者
潘丁龙
黄坚候
PAN Ding-long;HUANG Jian-hou(Department of Radiation Oncology,the Second Affiliated Hospital of Fujian Medical University,Quanzhou FUJIAN 362000,China;Department of Pharmacy,the First Hospital of Quanzhou,Quanzhou FUJIAN 362000,China)
出处
《中国新药与临床杂志》
CAS
CSCD
北大核心
2023年第4期222-225,共4页
Chinese Journal of New Drugs and Clinical Remedies
